LONDON (Reuters) - U.S. drugmaker Pfizer kept up the pressure on bid target AstraZeneca on Tuesday, saying its offer represented compelling value for a company which would otherwise face challenges as a standalone firm.
PFIZER (PFE.NY)released a statement to set out its case for the deal, just hours before its chief executive appears in front of a British parliamentary committee to explain why he wants to acquire Britain's second largest drugmaker.
ASTRAZENECA (AZN.LO)has rejected a $106 billion bid from Pfizer but the U.S. group is widely expected to return with a higher offer later this week.
(Reporting by Kate Holton; Editing by Neil Maidment)
Relacionados
- Pfizer se defiende mientras sopesa futuras acciones sobre AstraZeneca
- AstraZeneca shares gain on speculation of new Pfizer bid
- Cameron analizará la oferta de Pfizer por AstraZeneca para asegurar el empleo
- Cameron dice que quiere analizar la oferta de Pfizer por AstraZeneca
- Pfizer gana un 15% menos a la espera del 'sí' de AstraZeneca
